Opportunities for Treg cell therapy for the treatment of human disease
JA Bluestone, BS McKenzie, J Beilke… - Frontiers in …, 2023 - frontiersin.org
Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing
autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population …
autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population …
Boosting regulatory T cell function for the treatment of autoimmune diseases–That's only half the battle!
J Schlöder, F Shahneh, FJ Schneider… - Frontiers in …, 2022 - frontiersin.org
Regulatory T cells (Treg) represent a subset of specialized T cells that are essential for the
regulation of immune responses and maintenance of peripheral tolerance. Once activated …
regulation of immune responses and maintenance of peripheral tolerance. Once activated …
Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE
Background Umbilical cord blood (UCB)-derived CD4+ CD25+ CD127low regulatory T cells
(Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus …
(Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus …
The impact of regulatory T cells on the graft-versus-leukemia effect
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is the only curative therapy
for many hematologic malignancies, whereby the Graft-versus-Leukemia (GVL) effect plays …
for many hematologic malignancies, whereby the Graft-versus-Leukemia (GVL) effect plays …
Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes
K Zeng, H Ma, M Huang, MA Lyu, T Sadeghi… - Frontiers in …, 2024 - frontiersin.org
Background Adoptive therapy with umbilical cord blood (UCB) T-regulatory (Treg) cells can
prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and …
prevent graft vs. host disease (GVHD). We hypothesize that UCB Tregs can treat GVHD and …
A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease
A Salhotra, L Falk, G Park, K Sandhu, H Ali… - Expert Review of …, 2024 - Taylor & Francis
Introduction Patients with chronic graft versus host disease (cGVHD) have low circulating
regulatory T cells (Tregs). Interleukin-2 (IL-2) is a growth factor for Tregs, and clinical trials …
regulatory T cells (Tregs). Interleukin-2 (IL-2) is a growth factor for Tregs, and clinical trials …
Targeted Demethylation of FOXP3-TSDR Enhances the Suppressive Capacity of STAT6-deficient Inducible T Regulatory Cells
In vitro induced T regulatory cells (iTregs) are promising for addressing inflammation-driven
diseases. However, current protocols for the generation and expansion of iTregs fail to …
diseases. However, current protocols for the generation and expansion of iTregs fail to …
Efficacy of Ruxolitinib in the management of chronic GVHD
Objectives Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially
curative treatment for hematological diseases, with success rates improving due to …
curative treatment for hematological diseases, with success rates improving due to …
Allogeneic Hemopoietic Cell Transplantation as a Paradigm for Cellular Immunotherapy
AV Weiss-Haug, RA Haraszti, S Hug, C Faul… - Oncology Research …, 2025 - karger.com
Background: Allogeneic hematopoietic cell transplantation (alloHCT) is an established
curative treatment for hematologic malignancies and other severe blood disorders …
curative treatment for hematologic malignancies and other severe blood disorders …
Opportunities for Therapies for Graft-versus-host disease Following Hematopoietic Stem Cell Transplantation: Is Africa Prepared?
C Mangare - Journal of Medical and Biomedical Laboratory …, 2024 - jmblsr.com
Hematopoietic stem cell transplantation is a therapeutic approach used to cure many
malignant and non-malignant, acquired and congenital/genetic as well as benign disorders …
malignant and non-malignant, acquired and congenital/genetic as well as benign disorders …